{"id":"anti-cd25-mab","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Infection (opportunistic and bacterial)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Lymphopenia"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":{"chemblId":"CHEMBL5315106","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CD25 is the alpha subunit of the high-affinity IL-2 receptor, predominantly expressed on regulatory T cells (Tregs) and activated T lymphocytes. By targeting CD25, this antibody can deplete Tregs to enhance anti-tumor immunity or modulate T cell activation in autoimmune/inflammatory conditions. The mechanism allows selective immunomodulation depending on the disease context and dosing strategy.","oneSentence":"Anti-CD25 monoclonal antibody binds to the IL-2 receptor alpha chain (CD25) on activated T cells, depleting or inhibiting regulatory T cells and activated effector T cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:08.625Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (lymphomas, leukemias)"},{"name":"Solid tumors (as immunomodulatory agent in combination regimens)"}]},"trialDetails":[{"nctId":"NCT07217301","phase":"PHASE3","title":"IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed","status":"RECRUITING","sponsor":"Fortvita Biologics (USA)Inc.","startDate":"2025-11-26","conditions":"iO Resistant sqNSCLC","enrollment":600},{"nctId":"NCT05267626","phase":"PHASE1, PHASE2","title":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer","status":"RECRUITING","sponsor":"Aulos Bioscience, Inc.","startDate":"2022-04-04","conditions":"Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma","enrollment":159},{"nctId":"NCT04871607","phase":"PHASE2","title":"Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-02","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":33},{"nctId":"NCT04409080","phase":"PHASE1","title":"REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-01-13","conditions":"Severe Aplastic Anemia (SAA)","enrollment":17},{"nctId":"NCT06650553","phase":"NA","title":"Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2024-06-01","conditions":"Aplastic Anemias","enrollment":110},{"nctId":"NCT06880419","phase":"PHASE2","title":"Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-03","conditions":"Acute Graft-versus-Host Disease","enrollment":174},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT07059156","phase":"PHASE2, PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT05139004","phase":"PHASE1","title":"90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-07-19","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":7},{"nctId":"NCT07029958","phase":"PHASE4","title":"Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2024-11-12","conditions":"EBV-T/NK LPD","enrollment":48},{"nctId":"NCT01059786","phase":"PHASE2","title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-01","conditions":"Hairy Cell Leukemia","enrollment":69},{"nctId":"NCT05054361","phase":"","title":"Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2022-01-01","conditions":"Type1diabetes","enrollment":180},{"nctId":"NCT01476839","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2012-11-09","conditions":"Recurrent Adult Hodgkin Lymphoma","enrollment":25},{"nctId":"NCT02342782","phase":"PHASE1","title":"Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-06-08","conditions":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT06657391","phase":"PHASE2","title":"Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia","status":"RECRUITING","sponsor":"Rongrong Liu","startDate":"2024-10-01","conditions":"Transfusion Dependent Thalassemia","enrollment":396},{"nctId":"NCT06620822","phase":"PHASE2","title":"Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-09-30","conditions":"Non Small Cell Lung Cancer","enrollment":296},{"nctId":"NCT04936841","phase":"PHASE2","title":"Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2021-08-05","conditions":"Head and Neck Cancer","enrollment":5},{"nctId":"NCT00321555","phase":"PHASE2","title":"LMB-2 to Treat Hairy Cell Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-05-02","conditions":"Hairy Cell Leukemia","enrollment":15},{"nctId":"NCT06066840","phase":"PHASE4","title":"Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-08-01","conditions":"Safety and Efficacy","enrollment":45},{"nctId":"NCT01172418","phase":"PHASE4","title":"Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols","status":"COMPLETED","sponsor":"University of Miami","startDate":"2006-02","conditions":"Transplant; Failure, Kidney","enrollment":200},{"nctId":"NCT00870818","phase":"NA","title":"Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)","status":"TERMINATED","sponsor":"MacroGenics","startDate":"2009-02","conditions":"Type 1 Diabetes Mellitus","enrollment":219},{"nctId":"NCT04738981","phase":"PHASE3","title":"Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2021-02-01","conditions":"Graft Vs Host Disease","enrollment":130},{"nctId":"NCT02689453","phase":"PHASE1","title":"Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-19","conditions":"T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL)","enrollment":11},{"nctId":"NCT01468311","phase":"PHASE1, PHASE2","title":"Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-10-11","conditions":"Hodgkin Disease, Hodgkin Lymphoma","enrollment":6},{"nctId":"NCT05021276","phase":"PHASE4","title":"Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-12-15","conditions":"Safety and Efficacy","enrollment":50},{"nctId":"NCT00001962","phase":"PHASE2","title":"A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure","status":"TERMINATED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-11","conditions":"Aplastic Anemia, Pure Red Cell Aplasia, Diamond Blackfan Anemia","enrollment":100},{"nctId":"NCT04337593","phase":"PHASE2","title":"Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2020-06-01","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":20},{"nctId":"NCT00077922","phase":"PHASE2","title":"Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-02-29","conditions":"Leukemia, Lymphocytic, Chronic","enrollment":15},{"nctId":"NCT02843841","phase":"NA","title":"Polyclonal Antilymphocyte Globulin (ATG) & Intestinal Immune Barrier After Kidney Transplantation","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2014-12","conditions":"Disorder Related to Renal Transplantation","enrollment":63},{"nctId":"NCT00023244","phase":"PHASE2","title":"Steroid Withdrawal in Pediatric Kidney Transplant Recipients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-01","conditions":"End-Stage Renal Disease","enrollment":274},{"nctId":"NCT02561767","phase":"PHASE1, PHASE2","title":"Effect of BM-MSCs in DCD Kidney Transplantation","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-10","conditions":"Kidney Transplantation, Acute Kidney Tubular Necrosis","enrollment":120},{"nctId":"NCT00604357","phase":"PHASE3","title":"CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2008-12","conditions":"End Stage Liver Disease, Impaired Renal Function","enrollment":27},{"nctId":"NCT00001941","phase":"PHASE1, PHASE2","title":"Anti-Tac for Treatment of Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-12","conditions":"HTLV-I Infection, T Cell Leukemia","enrollment":34},{"nctId":"NCT00073047","phase":"PHASE2","title":"Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Facet Biotech","startDate":"2003-04","conditions":"Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease","enrollment":150},{"nctId":"NCT00050661","phase":"PHASE1, PHASE2","title":"To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"1997-10","conditions":"Psoriasis","enrollment":6},{"nctId":"NCT00050648","phase":"PHASE1, PHASE2","title":"To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"1997-10","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT00847106","phase":"PHASE1, PHASE2","title":"Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2004-03","conditions":"Melanoma","enrollment":15},{"nctId":"NCT00109161","phase":"PHASE2","title":"Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"PDL BioPharma, Inc.","startDate":"2005-04","conditions":"Multiple Sclerosis","enrollment":270},{"nctId":"NCT00049725","phase":"PHASE2","title":"Daclizumab to Treat Chronic Immune Thrombocytopenia","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2002-11","conditions":"Thrombocytopenia","enrollment":24},{"nctId":"NCT00040248","phase":"PHASE2","title":"Daclizumab to Treat Wegener's Granulomatosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-06","conditions":"Wegener's Granulomatosis","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Basiliximab"],"phase":"phase_3","status":"active","brandName":"Anti-CD25 mAb","genericName":"Anti-CD25 mAb","companyName":"Peking University People's Hospital","companyId":"peking-university-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-CD25 monoclonal antibody binds to the IL-2 receptor alpha chain (CD25) on activated T cells, depleting or inhibiting regulatory T cells and activated effector T cells. Used for Hematologic malignancies (lymphomas, leukemias), Solid tumors (as immunomodulatory agent in combination regimens).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}